HR1492Referred to Committee

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Introduced

In Committee

Passed One Chamber

Passed Both

Signed into Law

119th

Congress

2025-02-21

Introduced

Cosponsors

ⓘ

Type

Sponsor

Gregory F. Murphy

Republican · NC · Representative

Votes with party: 98.9% (468 recorded votes)

Full profile: /officials/M001210

Source: Congress.gov · FEC

Cosponsors (67)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2025-02-21

Source: Congress.gov

Committee Activity

Currently in

House Committee on Energy and CommerceReferred To · 2025-02-21
House Committee on Ways and MeansReferred To · 2025-02-21

Previously

Energy and Commerce CommitteeReferred To · 2025-02-21
Ways and Means CommitteeReferred To · 2025-02-21

Plain-English Summary

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation. The bill's changes apply retroactively.

Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.

Subjects

Health

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 1492 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. R. 1492 To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES February 21, 2025 Mr. Murphy (for himself, Mr. Davis of North Carolina, and Mr. Hudson) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. EQUALIZING THE NEGOTIATION PERIOD BETWEEN SMALL-MOLECULE AND BIOLOGIC CANDIDATES UNDER THE DRUG PRICE NEGOTIATION PROGRAM. (a) In General.--Section 1192(e)(1)(A)(ii) of the Social Security Act (42 U.S.C. 1320f-1(e)(1)(A)(ii)) is amended by striking ``7 years'' and inserting ``11 years''. (b) Effective Date.--The amendment made by subsection (a) shall take effect as if included in the enactment of Public Law 117-169. <all>

Open clean-text view Read on Congress.gov →

Related legislation

Bills by the same sponsor or covering overlapping subjects.

HR8163Provider Reimbursement Stability Act of 2026
Referred to Committee · 2026-05-21
HR6583VA Research Reform Act of 2025
Referred to Committee · 2026-05-20
HR8553To direct the Secretary of Veterans Affairs to establish a precision oncology program for cancer of the prostate, and for other purposes.
Referred to Committee · 2026-04-28
HR8344Senior Citizens’ Freedom to Work Act of 2026
Referred to Committee · 2026-04-16